METHYS Dx
Created in 2021
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
625Activities
Technologies
Entity types
Location
67 Rue Saint-Jacques, 75005 Paris, France
Paris
France
Employees
Scale: 11-50
Estimated: 15
Engaged corporates
21
7 4Added in Motherbase
10 months, 2 weeks ago
deeptech Value proposition
Innovating for cancer patients
METHYS Dx develops innovative liquid biopsy tests for non-invasive monitoring of cancer patients. Combining unique proprietary molecular signatures and a disruptive ultrasensitive detection technology, METHYS Dx tests will allow monitoring of tumor evolution, and early detection of relapses, thus improving patient care through better-informed therapeutic decisions.
ctDNA, Cancer, Biomarqueurs, circulating tumoral DNA, Liquid biopsy, Precision medicine, and ddPCROriginal language
Innovating for cancer patients
METHYS Dx develops innovative liquid biopsy tests for non-invasive monitoring of cancer patients. Combining unique proprietary molecular signatures and a disruptive ultrasensitive detection technology, METHYS Dx tests will allow monitoring of tumor evolution, and early detection of relapses, thus improving patient care through better-informed therapeutic decisions.
Innovative tests for cancer patient monitoring | Methys DX
https://methysdx.com/en/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Other 5 Jul 2023 | | |